Skip to main content

UCS Market update

I did not post yesterday because it seemed like business as usual. Markets are expected to rise today according to a before-the-bell report listed on the WSJ online.

However, the major indexes that represent most aspects of the markets are still trading very tightly. Hardly any buyers; again it seems like there is this shifting of money around- from one account to another. It's funny that when you have a lot of time on your hands that that is the time when you notice things that you may not have noticed before, such as the net assets of many ETFs. They are not increasing! This could be a problem or maybe not.

On another note, I still have not answered the question of 'What to buy- foreign or domestic', from my previous posts on Wednesday June, 24th. I will try to make another attempt to provide some clues today.

7/1/2009 9:15 AM

Comments

Popular posts from this blog

Morning Update

By Rick Walter Still working on putting together a strong biotech portfolio. Here is a good general article on the state of the biotech industry that was posted yesterday on the online Wall Street Journal's site- Biotech Stocks Hot Right Now, Ho-Hum in the Long Run.

Portfolio Update

By Rick Walter I have posted a new Biotechnology portfolio . It's total return as of November 25, 2009 is 3.4%. However, to download and use it you will have to subscribe to the portfolio, of course. On an important note, I consider each portfolio to be well diversified in its particular sector but I've recently decided to add stock futures and options positions to each portfolio which will increase each portfolio's return but lower the risks going forward.

Biotech Pump and Dump

By Rick Walter Building a good Biotechnology portfolio has turned out to be a bit of a task. I have one on the table, but feel that it's a little too aggressive and risky, especially for today's market. Funding for most Biotech ventures- old or new, have either dried up or have been put on hold. This portfolio that I am building is too much of a pure Biotech play. It would be feast or famine on the returns. Let me explain. I remember when I was a young broker, I worked for this small outfit in Florida where the office manager and a few other brokers, including myself, would get all pumped up over a stock called Celi. I believe that the stock is now trading on the Amex as (Cel-Sci: CVM ). Well the stock was always on the verge of getting approval for some phase of cancer treatment therapy. Whenever the company released news, we would run the stock up as high as the market makers would let us run it- ($1.30 to $2.30 per share) before we banged it back down to previous lows of .30...